Saras Capital Research
Investment Thesis
Saras Capital is a London-based, Europe-focused venture firm investing at the intersection of biology and artificial intelligence. Founded in 2020 by Nadav Rosenberg, the firm describes its own posture as "a venture firm with an angel-like approach for company founders and an institutional interface for limited partners," aspiring to be "the best minority shareholders in the world." The firm believes biotech is undergoing a transformation as profound as cloud computing was for software, driven by large-scale sequencing, generative AI models, and lab automation converging with a new generation of technically fluent, commercially minded founders.
The firm's stated focus rests on three pillars: Founders, Europe, and AI. On founders, Saras explicitly weights execution, commercial instinct, and talent-and-capital-attraction ability alongside the underlying science, and is comfortable backing scientifically brilliant teams even before a finalized indication or modality. On geography, the firm is "Europe-centric yet globally minded," actively sourcing across the UK, Israel, the DACH region, France, and the Nordics, arguing that Europe's strong data-protection and regulatory frameworks are an underappreciated advantage in a heavily regulated industry, alongside a large underserved healthcare market.
Sector Focus
Saras organizes its AI thesis around three sub-themes: (1) AI Discovery Platforms — companies using AI to identify novel drug targets or candidates, often starting as pharma partnership platforms before building proprietary pipelines; (2) "Biotech in a Garage" — small, agile teams using next-generation tools and third-party infrastructure to move from concept to clinic faster and cheaper; and (3) Vertical AI & SaaS for Biopharma — software applied to clinical trials, regulatory workflows, and R&D operations to drive step-change efficiency. The firm explicitly avoids single-asset therapeutics, consumer health, and fundamental research plays without a clear commercial or platform angle.
Stage Focus & Check Size
Saras invests early, from pre-seed through seed, and states it is "often the first to commit to a round," helping catalyse syndicates before stepping back into a quieter, advice-on-request posture. No specific check-size range is published; historical rounds the firm has participated in span roughly $500K pre-seed rounds up to multi-million-dollar seed rounds (e.g., a €5.5M seed for kyron.bio and a £7M/$9.4M seed for Biographica), with at least one earlier Series A lead (Flexciton, 2021) predating the firm's current pre-seed/seed focus.
Recent Activity
Saras closed its second vehicle, Saras Capital II LP, with a final close announced in January 2026 (advised by Haynes Boone), continuing the same thesis with LPs including Isomer Capital. Recent portfolio activity includes participation in kyron.bio's €5.5M seed (May 2025, led by HCVC), Cellbyte's $2.75M seed (November 2025, led by Frontline Ventures), and Biographica's £7M/$9.4M seed (January 2026, led by Faber VC). The fund appears actively deploying.
Portfolio Highlights
Confirmed portfolio companies span AI-native biopharma and biotech tooling: Shennon Biotechnologies (T-cell engager discovery), Infinitopes (cancer vaccine viral vectors), Biographica (AI-driven crop gene-editing target discovery), Cellbyte (AI platform for pharma launch and market access), kyron.bio (AI-driven antibody glycoengineering), Converge Bio (AI-powered antibody design), Neobe Therapeutics (synthetic biology cancer immunotherapy), and Flexciton (AI-driven semiconductor fab scheduling, an earlier and more sector-adjacent bet).
Team
- Nadav Rosenberg, Founder & Managing Partner — Prior Venture Partner at Entrepreneur First and General Manager at Taboola; writes and speaks publicly on tech-bio investing (LinkedIn essay series, SynBioTech speaker).
- Ben Prince, Finance and Operations Director — Runs finance and operations for the fund; quoted in the firm's Fund II close announcement.
- Joe Healey, Venture Partner — Also Founder of NanoSyrinx (a synthetic-biology drug-delivery company); sits on DSIT's Engineering Biology Advisory Panel and reviews for BBSRC's Pool of Experts.
Decision Process
Given the small team size and that Nadav Rosenberg is the sole named spokesperson across every public announcement and press quote, decision-making appears concentrated with the Managing Partner (solo-GP style) rather than a formal investment committee.
Founder Preferences
Saras looks for founders who combine technical brilliance with commercial instinct: scientists who code, engineers who understand biology, and teams capable of attracting both talent and capital. The firm is comfortable investing before a finalized indication or modality if founder execution, clarity, and drive are evident.
Geographic Focus
Europe-centric with global outlook: UK, Israel, DACH region, France, and the Nordics are named explicitly as areas of focus, reflecting Rosenberg's thesis that underappreciated pockets of biology and computer-science talent exist across these markets relative to the US-dominated industry narrative.